Pharma Sector Analysis in India (Listed Companies on Stock Exchange)

This analysis is done with the only purpose of screening out good companies. Analysis done is completely on quantitative basis. No suggestions are being made to directly go and invest in the top scoring companies of this analysis.

Let’s study some Pharma companies, we have selected the following companies for study and analysis (the companies are selected on the basis of market cap, the top 8 companies of that sector according to market cap): –

1. Sun Pharma
2. Dr. Reddys
3. Aurobindo Pharma
4. Cipla
5. Divis Lab
6. Lupin Pharmaceuticals
7. Biocon
8. Cadila Healthcare

Sr. No.	Company Name	Market Cap (Rs. Crore)
1	Sun Pharma	103,842
2	Dr. Reddys	43,203
3	Aurobindo Pharma	42,501
4	Cipla	41,362
5	Divis Lab	38,721
6	Lupin	37,495
7	Biocon	37,101
8	Cadila Healthcare	35,282

The top 100 companies according to the market capitalization are called as the large cap companies. Companies from 101 to 250 (based on market capitalization) are the mid-cap companies and the rest, that is above 250 are the small cap companies.

All the companies here are large cap companies.

The analysis of these companies is going to be based on the following parameters. They are as follows: –

1. Price-to-Earnings (PE) Ratio
2. What is ROCE (Return on Capital Employed)
3. What is ROE (Retuen on Equity)
4. Debt to Equity Ratio (DE Ratio)
5. 5 Years Sales Growth
6. 5 Years Net Profit Growth

These parameters play an important role in the analysis of any company. This does not mean that one should be dependent only on these, but these parameters are crucial for initial screening.

First, we have given the companies their ranks and then accordingly we have assigned scores to those companies from 1 to 8, where 1 being the least and 8 being highest score. (total number of companies taken here are 8, that’s why the mentioned scoring card)

PE Ratio

Sr. No.	Company Name	PE Ratio	Rank	Score
1	Sun Pharma	28.34	4	5
2	Dr. Reddys	27.51	3	6
3	Aurobindo Pharma	19.23	2	7
4	Cipla	28.39	5	4
5	Divis Lab	33.71	7	2
6	Lupin	30.46	6	3
7	Biocon	68.91	8	1
8	Cadila Healthcare	17.51	1	8

PE ratio is nothing but what price an investor is paying for 1 rupee of earning.

The company which has the highest PE ratio has been given number 8^th rank and the company which has the lowest PE ratio has been given number 1^st rank.

But the company which has the highest PE ratio has been given the lowest score.

Biocon has the highest PE ratio and thus got number 8^th rank and scored 1. Cadila Healthcare has the lowest PE ratio and thus scored number 1^st rank and a score of 8.

ROCE

Sr. No.	Company Name	ROCE	Rank	Score
1	Sun Pharma	10.41%	4	5
2	Dr. Reddys	7.75%	8	1
3	Aurobindo Pharma	22.85%	1	8
4	Cipla	9.64%	6	3
5	Divis Lab	21.37%	2	7
6	Lupin	10.21%	5	4
7	Biocon	8.41%	7	2
8	Cadila Healthcare	18.28%	3	6

The company which has the highest ROCE has the highest rank and has also been given the highest points. And the company which has the lowest ROCE has the lowest rank and has also been given the lowest score.

Aurobindo Pharma has the number 1 rank and scored 8 points. And Dr. Reddys has the lowest rank (8^th) and scored 1 point.

ROE

Sr. No.	Company Name	ROE	Rank	Score
1	Sun Pharma	7.70%	5	4
2	Dr. Reddys	7.19%	6	3
3	Aurobindo Pharma	23.13%	1	8
4	Cipla	10.06%	4	5
5	Divis Lab	15.34%	3	6
6	Lupin	2.08%	8	1
7	Biocon	6.56%	7	2
8	Cadila Healthcare	22.64%	2	7

ROE has been analyzed on the same basis as ROCE.

The company which has the highest ROE has the highest rank and has also been given the highest points. And the company which has the lowest ROE has the lowest rank and has also been given the lowest score.

Here too, Aurobindo Pharma ranked 1^st as it had the highest ROE and thus scored 8. But here, Lupin ranked 8^th as it had the lowest ROE and thus scored 1.

DE Ratio

Sr. No.	Company Name	DE Ratio	Rank	Score
1	Sun Pharma	0.27	7	7
2	Dr. Reddys	0.4	5	5
3	Aurobindo Pharma	0.41	4	4
4	Cipla	0.29	6	6
5	Divis Lab	0.01	8	8
6	Lupin	0.53	2	2
7	Biocon	0.44	3	3
8	Cadila Healthcare	0.62	1	1

A lower DE ratio means that the company doesn’t require debt for its growth or for its working capital. That is the debt component of that company is very low and it can run its operations smoothly using the existing equity or reserves & surplus.

The company which has the highest DE ratio has the least score and the company with lowest DE ratio has the highest score.

Divis Lab has the lowest DE ratio and has thus scored 8. Cadila Healthcare has the highest DE ratio and has thus scored 1.

 5 Years Growths

Sr. No.	Company Name	5 Years Sales Growth	Rank	Score
1	Sun Pharma	18.94%	2	7
2	Dr. Reddys	3.83%	8	1
3	Aurobindo Pharma	23.02%	1	8
4	Cipla	12.85%	4	5
5	Divis Lab	12.38%	5	4
6	Lupin	10.38%	7	2
7	Biocon	10.66%	6	3
8	Cadila Healthcare	13.37%	3	6

Sr. No.	Company Name	5 Years Net Profit Growth	Rank	Score
1	Sun Pharma	-3.09%	6	3
2	Dr. Reddys	-10.04%	7	2
3	Aurobindo Pharma	52.08%	1	8
4	Cipla	-2.45%	5	4
5	Divis Lab	7.36%	3	6
6	Lupin	-26.63%	8	1
7	Biocon	-0.87%	4	5
8	Cadila Healthcare	22.02%	2	7

The company with the highest 5 Year CAGR in Sales and Net Profit get the highest rank and thus gets the highest score. And Vice-Versa.

Aurobindo Pharma has scored 8 in both, as it has the highest 5 years sales & net profit growth. And Dr. Reddys has scored 1 in 5 Year Sales Growth and Lupin has scored 1 in 5 Year Net Profit Growth, as they have the lowest 5 years sales & net profit growth.

Final Standings

Rank	Company Name	Final Score
1	Aurobindo Pharma	43
2	Cadila Healthcare	35
3	Divis Lab	33
4	Sun Pharma	31
5	Cipla	27
6	Dr. Reddys	18
7	Biocon	16
8	Lupin	13

Aurobindo Pharma is on the 1^st position with 43 points, Cadila Healthcare on 2^nd with 35 points, Divis Lab on 3^rd with 33 points and Lupin is on the last position, that is 8^th with just 13 points.

The point here is to focus on the fundamentals of the company. Here, we have analyzed the company based on their current fundamentals. Also, the qualitative analysis of these companies will provide with a better outlook towards them

And quantitative analysis along with qualitative analysis will give a better understanding of which company is worth investing from here on.

Note: –

• We are not, in any case, suggesting buying stocks of any of the companies mentioned above. We have just provided a study on these companies.
• All the data used is of Trailing Twelve Month (TTM)